FDA/CDC Active Surveillance System Could Assess Effect Of Safety Measures
Executive Summary
A collaborative national electronic active surveillance system co-sponsored by FDA and the Centers for Disease Control & Prevention could be used to examine the impact of safety measures on the number of adverse drug events, CDC medical officer Dan Budnitz said July 7